Navigation Links
Ceregene Reports Data From Parkinson's Disease Phase 2b Study
Date:4/19/2013

SAN DIEGO, April 19, 2013 /PRNewswire/ -- Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.   The trial did not demonstrate statistically significant efficacy on the primary endpoint (UPDRS-motor off). However, one of the "key secondary endpoints" (Diary-off score), as defined and prespecified in the Statistical Analysis Plan, did produce statistically significant benefit. The trial also provided further evidence for the safety of CERE-120 and the dosing methods employed. A marked placebo effect was observed in this trial in that both the sham-surgery-control patients and the CERE-120 treated patients showed significant improvement following their surgery.

Fifty-one (51) patients with moderately advanced Parkinson's disease who could not be satisfactorily controlled with conventional Parkinson's medication were enrolled in the study at 11 leading clinical sites throughout the U.S.  Approximately half of the patients received CERE-120 while the other half received sham (placebo) surgery as a control.  Patients were monitored for 15-24 months to assess safety and changes in Parkinson's disease symptoms, using multiple endpoints such as the Unified Parkinson's Disease Rating Scale (UPDRS), Daily Diaries that assess motor function throughout the day, and PDQ-39 (a measure of quality of life), among others. Ceregene continues to analyze the data from this trial to gain as much information as possible.

Jeffrey M. Ostrove , Ph.D., president and chief executive officer of Ceregene, Inc. stated, "We are disappointed that we did not achieve broader statistical significance in this small clinical trial, perhaps due in part to the marked placebo effect noted above.  That said, we at
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (MIPT and Russian Quantum Center at Skolkovo) and ... and the Institute of Physics in Bratislava, Slovakia) ... of particles passing through an amplifier and, conversely, ... are provided in an article published in the ... , Quantum entangled particles are considered to be ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Last year, ... Systems , a leading global provider of data management ... with TrialMaster, a leading-edge system for electronic data capture ... of universal design and study execution tools added TrialMaster ... and much anticipated version of Transform for TrialMaster, is ...
(Date:7/23/2014)... DuPont Pioneer announced today that Neal Gutterson, ... Agricultural Biotechnology (ABT), effective July 21, 2014. Gutterson joins ... as president, chief executive officer and board member. , ... seed and crop protection industry to this integral role ... president of DuPont Pioneer. “I am looking forward to ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2
... Hard-to-transfect Cells , Dmitriy ... Kelnar, David Brown, Ambion, Inc. , ... RNA interference (RNAi) is a powerful , ... genes. It is used routinely for gene function analysis, target , ...
... Trace amounts of ribonuclease (RNase) , ... ubiquitous in the laboratory environment--on your skin, in the , ... , open to the air--it ... or eliminate RNase contamination. However, determining which , ...
... , High Quality Custom Synthesis ... Mouse, and Rat , Genomes , ... Silencer siRNA Libraries , , ... Quality Custom RNA Synthesis by Ambion Finding a highly effective ...
Cached Biology Technology:Delivering siRNAs to Difficult Cell Types 2Delivering siRNAs to Difficult Cell Types 3Delivering siRNAs to Difficult Cell Types 4Delivering siRNAs to Difficult Cell Types 5Delivering siRNAs to Difficult Cell Types 6Delivering siRNAs to Difficult Cell Types 7Combat RNase Contamination in the Lab 2Combat RNase Contamination in the Lab 3Combat RNase Contamination in the Lab 4Combat RNase Contamination in the Lab 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 2IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 3IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 4IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 6IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 7IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 8IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 9IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 10
(Date:7/23/2014)... potential for clinical use of induced pluripotent stem ... previously been hindered by the risk of dysregulated ... ability to use etoposide treatment to halt teratoma ... disease, specifically acute myocardial infarction, is demonstrated in ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:7/23/2014)... do mollusks, starfish, and corals have in common? ... all calcifiersorganisms that use calcium from their environment ... stability and protection. , The July issue of ... Marine Biological Laboratory, addresses the challenges faced by ... As atmospheric carbon dioxide rises, the world,s oceans ...
(Date:7/23/2014)... Massachusetts , July 23, 2014 ... in its new report, GLOBAL MARKETS AND TECHNOLOGIES ... related technologies is expected to grow to nearly $154.4 ... rate (CAGR) of 10.1%. The image, flow, and level ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Biology News(10 mins):Calcification in changing oceans explored in special issue of The Biological Bulletin 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3
... fractures occur in the United States as a result of ... to rapid bone fusion but with limited mechanical strength often ... difficult to harvest without pain and severe morbidity. Funded by ... the Department of Chemistry, Chemical Biology and Biomedical Engineering at ...
... Washington two years ago launched an ambitious project harnessing the ... Foldit, turns one of the hardest problems in molecular biology ... people have now played a game that asks them to ... a princess. Results published Thursday (Aug. 5) in the ...
... shallow, nearshore waters, researchers from Stony Brook University ... first multi-year survey of the population of Antarctic ... near Livingston Island and discovered that nearshore waters ... waters. They also found that the nearshore waters ...
Cached Biology News:NSF funds innovative approach to biomimetic nanofiber bone regeneration 2NSF funds innovative approach to biomimetic nanofiber bone regeneration 3Gaming for a cure: Computer gamers tackle protein folding 2Gaming for a cure: Computer gamers tackle protein folding 3Gaming for a cure: Computer gamers tackle protein folding 4First nearshore survey of Antarctic krill reveals high density, stable population in shallow waters 2
Request Info...
FITC~Bovine Serum Albumin...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Silencer Pre-designed siRNAs, which are already designed ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: